Share-based Payment Arrangement, Expense of SANGAMO THERAPEUTICS, INC from 31 Dec 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
SANGAMO THERAPEUTICS, INC quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Sep 2025.
  • SANGAMO THERAPEUTICS, INC Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,127,000, a 36% decline year-over-year.
  • SANGAMO THERAPEUTICS, INC Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $10,232,000, a 33% decline year-over-year.
  • SANGAMO THERAPEUTICS, INC annual Share-based Payment Arrangement, Expense for 2024 was $12,382,000, a 55% decline from 2023.
  • SANGAMO THERAPEUTICS, INC annual Share-based Payment Arrangement, Expense for 2023 was $27,363,000, a 14% decline from 2022.
  • SANGAMO THERAPEUTICS, INC annual Share-based Payment Arrangement, Expense for 2022 was $31,650,000, a 4% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

SANGAMO THERAPEUTICS, INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $10,232,000 $2,127,000 -$1,188,000 -36% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $11,420,000 $2,226,000 -$839,000 -27% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $12,259,000 $2,596,000 -$123,000 -4.5% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $12,382,000 $3,283,000 -$2,824,000 -46% 01 Oct 2024 31 Dec 2024 10-K 17 Mar 2025 2024 FY
Q3 2024 $15,206,000 $3,315,000 -$2,874,000 -46% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $18,080,000 $3,065,000 -$3,725,000 -55% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $21,805,000 $2,719,000 -$5,558,000 -67% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $27,363,000 $6,107,000 -$2,141,000 -26% 01 Oct 2023 31 Dec 2023 10-K 17 Mar 2025 2024 FY
Q3 2023 $29,504,000 $6,189,000 -$1,604,000 -21% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $31,108,000 $6,790,000 -$1,128,000 -14% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $32,236,000 $8,277,000 +$586,000 +7.6% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $31,650,000 $8,248,000 +$172,000 +2.1% 01 Oct 2022 31 Dec 2022 10-K 13 Mar 2024 2023 FY
Q3 2022 $31,478,000 $7,793,000 -$80,000 -1% 01 Jul 2022 30 Sep 2022 10-Q 01 Nov 2023 2023 Q3
Q2 2022 $31,558,000 $7,918,000 -$1,565,000 -17% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $33,123,000 $7,691,000 +$167,000 +2.2% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $32,956,000 $8,076,000 +$1,434,000 +22% 01 Oct 2021 31 Dec 2021 10-K 13 Mar 2024 2023 FY
Q3 2021 $31,522,000 $7,873,000 +$1,191,000 +18% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $30,331,000 $9,483,000 +$2,719,000 +40% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $27,612,000 $7,524,000 +$1,904,000 +34% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $25,708,000 $6,642,000 +$1,403,000 +27% 01 Oct 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
Q3 2020 $24,305,000 $6,682,000 +$1,981,000 +42% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $22,324,000 $6,764,000 +$1,897,000 +39% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $20,427,000 $5,620,000 +$1,097,000 +24% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021 2021 Q1
Q4 2019 $19,330,000 $5,239,000 +$936,000 +22% 01 Oct 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
Q3 2019 $18,394,000 $4,701,000 +$891,000 +23% 01 Jul 2019 30 Sep 2019 10-Q 04 Nov 2020 2020 Q3
Q2 2019 $17,503,000 $4,867,000 +$1,353,000 +39% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $16,150,000 $4,523,000 +$1,473,000 +48% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $14,677,000 $4,303,000 +$2,185,000 +103% 01 Oct 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
Q3 2018 $12,492,000 $3,810,000 +$1,591,000 +72% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $10,901,000 $3,514,000 +$1,550,000 +79% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $9,351,000 $3,050,000 +$262,000 +9.4% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $9,089,000 $2,118,000 +$189,000 +9.8% 01 Oct 2017 31 Dec 2017 10-K 28 Feb 2020 2019 FY
Q3 2017 $8,900,000 $2,219,000 -$516,000 -19% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $9,416,000 $1,964,000 -$5,235,000 -73% 01 Apr 2017 30 Jun 2017 10-Q 08 Aug 2018 2018 Q2
Q1 2017 $14,651,000 $2,788,000 -$406,000 -13% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $15,057,000 $1,929,000 -$1,137,000 -37% 01 Oct 2016 31 Dec 2016 10-K 01 Mar 2019 2018 FY
Q3 2016 $16,194,000 $2,735,000 -$93,000 -3.3% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $16,287,000 $7,199,000 +$4,316,000 +150% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q2
Q1 2016 $11,971,000 $3,194,000 +$241,000 +8.2% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1
Q4 2015 $11,730,000 $3,066,000 +$31,000 +1% 01 Oct 2015 31 Dec 2015 10-K 01 Mar 2018 2017 FY
Q3 2015 $11,699,000 $2,828,000 +$699,000 +33% 01 Jul 2015 30 Sep 2015 10-Q 27 Oct 2016 2016 Q3
Q2 2015 $11,000,000 $2,883,000 +$754,000 +35% 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016 2016 Q2
Q1 2015 $10,246,000 $2,953,000 +$1,046,000 +55% 01 Jan 2015 31 Mar 2015 10-Q 05 May 2016 2016 Q1
Q4 2014 $9,200,000 $3,035,000 +$987,000 +48% 01 Oct 2014 31 Dec 2014 10-K 28 Feb 2017 2016 FY
Q3 2014 $8,213,000 $2,129,000 +$738,000 +53% 01 Jul 2014 30 Sep 2014 10-Q 30 Oct 2015 2015 Q3
Q2 2014 $7,475,000 $2,129,000 +$751,000 +54% 01 Apr 2014 30 Jun 2014 10-Q 06 Aug 2015 2015 Q2
Q1 2014 $6,724,000 $1,907,000 +$578,000 +43% 01 Jan 2014 31 Mar 2014 10-Q 28 Apr 2015 2015 Q1
Q4 2013 $6,146,000 $2,048,000 +$721,000 +54% 01 Oct 2013 31 Dec 2013 10-K 18 Feb 2016 2015 FY
Q3 2013 $5,425,000 $1,391,000 -$13,000 -0.93% 01 Jul 2013 30 Sep 2013 10-Q 28 Oct 2014 2014 Q3
Q2 2013 $5,438,000 $1,378,000 +$154,000 +13% 01 Apr 2013 30 Jun 2013 10-Q 29 Jul 2014 2014 Q2
Q1 2013 $5,284,000 $1,329,000 -$54,000 -3.9% 01 Jan 2013 31 Mar 2013 10-Q 07 May 2014 2014 Q1
Q4 2012 $5,338,000 $1,327,000 01 Oct 2012 31 Dec 2012 10-K 25 Feb 2015 2014 FY
Q3 2012 $1,404,000 -$648,000 -32% 01 Jul 2012 30 Sep 2012 10-Q 04 Nov 2013 2013 Q3
Q2 2012 $1,224,000 -$742,000 -38% 01 Apr 2012 30 Jun 2012 10-Q 02 Aug 2013 2013 Q2
Q1 2012 $1,383,000 01 Jan 2012 31 Mar 2012 10-Q 09 May 2013 2013 Q1
Q3 2011 $2,052,000 01 Jul 2011 30 Sep 2011 10-Q 02 Nov 2012 2012 Q3
Q2 2011 $1,966,000 01 Apr 2011 30 Jun 2011 10-Q 03 Aug 2012 2012 Q2

SANGAMO THERAPEUTICS, INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $12,382,000 -$14,981,000 -55% 01 Jan 2024 31 Dec 2024 10-K 17 Mar 2025 2024 FY
2023 $27,363,000 -$4,287,000 -14% 01 Jan 2023 31 Dec 2023 10-K 17 Mar 2025 2024 FY
2022 $31,650,000 -$1,306,000 -4% 01 Jan 2022 31 Dec 2022 10-K 13 Mar 2024 2023 FY
2021 $32,956,000 +$7,248,000 +28% 01 Jan 2021 31 Dec 2021 10-K 13 Mar 2024 2023 FY
2020 $25,708,000 +$6,378,000 +33% 01 Jan 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
2019 $19,330,000 +$4,653,000 +32% 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
2018 $14,677,000 +$5,588,000 +61% 01 Jan 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
2017 $9,089,000 -$5,968,000 -40% 01 Jan 2017 31 Dec 2017 10-K 28 Feb 2020 2019 FY
2016 $15,057,000 +$3,327,000 +28% 01 Jan 2016 31 Dec 2016 10-K 01 Mar 2019 2018 FY
2015 $11,730,000 +$2,530,000 +28% 01 Jan 2015 31 Dec 2015 10-K 01 Mar 2018 2017 FY
2014 $9,200,000 +$3,054,000 +50% 01 Jan 2014 31 Dec 2014 10-K 28 Feb 2017 2016 FY
2013 $6,146,000 +$808,000 +15% 01 Jan 2013 31 Dec 2013 10-K 18 Feb 2016 2015 FY
2012 $5,338,000 -$2,743,000 -34% 01 Jan 2012 31 Dec 2012 10-K 25 Feb 2015 2014 FY
2011 $8,081,000 +$263,000 +3.4% 01 Jan 2011 31 Dec 2011 10-K 24 Feb 2014 2013 FY
2010 $7,818,000 01 Jan 2010 31 Dec 2010 10-K 26 Feb 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.